Human papillomavirus (HPV) is often transmitted through sexual partnerships. However, many previous HPV transmission models ignore the existence of partnerships by implicitly assuming that each new sexual contact is made with a different person. Here, we develop a simplified pair model—based on the example of HPV—that explicitly includes sexual partnership formation and dissolution. We show that not including partnerships can potentially result in biased projections of HPV prevalence. However, if transmission rates are calibrated to match empirical pre-vaccine HPV prevalence, the projected prevalence under a vaccination program does not vary significantly, regardless of whether partnerships are included.
References
[1]
Ault, KA. Human papillomavirus vaccine: an update for gynecologists. Clin. Obstet. Gynecol？2008, 51, 527–532.
[2]
Franco, EL; Harper, DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine？2005, 23, 2388–2394.
[3]
Ontario Government. Love alone won’t protect your grade 8 daughter from cervical cancer: Ontario’s Grade 8 Vaccination Program.
[4]
Clifford, G; Franceschi, S; Diaz, M; Munoz, N; Villa, LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine？2006, 24, S26–S34.
[5]
Walboomers, J; Jacobs, M; Manos, M; Bosch, F; Kummer, J; Shah, K; Snijder, P; Peto, J; Meijer, C; Munoz, N. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol？1999, 189, 1–3.
[6]
Bosch, FX; Lorincz, A; Munoz, N; Meijer, CJ; Shah, KV. The casual relation between human papillomavirus and cervical cancer. J. Clin. Pathol？2002, 55, 244–265.
[7]
Mu？oz, N. Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol？2000, 19, 1–5.
[8]
Parkin, D; Bray, F; Ferlay, J; Pisano, P. Global cancer statistics, 2002. CA Cancer J. Clin？2002, 55, 74–108.
[9]
Sankaranarayanan, R; Ferlay, J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol？2006, 20, 207–225.
[10]
Bleeker, MCG; Hogenwoning, CJ; Berkhiof, J; Voorhorst, FJ; Hesselink, AT; van Diemen, PM; van den Brule, AJC; Snijders, PJF; Meijer, CJ. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin. Infect. Dis？2005, 41, 612–620.
[11]
Hughes, JP; Garnett, GP; Koutsky, LA. The theoretical population-level impact of prophylactic human papillomavirus vaccine. Epidemiology？2002, 13, 631–639.
[12]
Baseman, JG; Koutsky, LA. Review: The epidemiology of human papillomavirus infections. J. Clin. Virol？2005, 32, S16–S24.
[13]
Franco, EL; Villa, LL; Sobrinho, J; Prado, J; Rousseau, M; Desy, M. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J. Infect. Dis？1999, 180, 1415–1423.
[14]
Giuliano, A; Harris, R; Sedjo, R; Baldwin, S; Roe, D; Papenfuss, MR; Abrahamsen, M; Inserra, P; Olvera, S; Hatch, K. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the young women's health study. J. Infect. Dis？2002, 186, 462–469.
[15]
Ho, GYF; Bierman, R; Beardsley, L; Chang, CJ; Burk, RD. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med？1998, 338, 432–428.
[16]
Richardson, H; Kelsall, G; Tellier, P; Voyer, H; Abrahamowicz, M; Ferenczy, A; Coutlée, F; Franco, EL. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomarker. Prev？2003, 12, 485–490.
[17]
Sellors, JW; Mahony, JB; Kaczorowski, J; Lytwyn, A; Bangura, H; Chong, S; Lorincz, A; Dalby, DM; Janjusevic, V; Keller, JL. The Survery of HPV in Ontario Women (SHOW) Group. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Can. Med. Assoc. J？2000, 163, 503–508.
[18]
zur Hausen, H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Nat. Cancer Inst？2000, 92, 690–698.
[19]
Bosch, F; de Sanjosé, S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of casualty. J. Nat. Cancer Inst. Monogram？2003, 31, 3–13.
[20]
Linneham, M; Groce, N. Counseling and educational interventions for women with genital human papillomavirus infection. AIDS Patient Care STDS？2000, 14, 439–445.
[21]
Centres for disease control and prevention. Sexually Transmitted Diseases Treatment Guideline 2002. Department of Health and Human Services: Centres for Disease Control and Prevention, 2002.
[22]
Koutsky, LA. Epidemiology of genital human papillomavirus infection. Amer. J. Med？1997, 102, 3–8.
[23]
Villa, LL. Prophylactic HPV vaccines reducing the burden of HPV-related diseases. Vaccine？2006, 24, S23–S28.
[24]
Foxman, B; Newman, M; Percha, B; Holmes, KK; Aral, SO. Measures of sexual partnerships: lengths, gaps, overlaps, and sexually transmitted infection. Sex. Transm. Dis？2006, 33, 209–214.
[25]
Elbasha, EH; Dashbach, EJ; Insinga, RP. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis？2007, 13, 28–41.
Barnabas, RV; Laukkanen, P; Koskela, P; Kontule, O; Lehtinen, M; Garnett, GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLOS Med？2006, 3, 624–632.
[28]
Paavonen, J; Naud, P; Salmeron, J; Wheeler, C; Chow, S; Apter, D. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet？2009, 374, 301–314.
[29]
Singh, A; Wong, T; Howlett, RI. Human papillomavirus vaccines: why the time is right to implement immunization and surveillance programs in Canada. Can. J. Infect. Dis. Med. Microbiol？2008, 19, 294–296.
[30]
Brown, DR; Fife, KH; Wheeler, CM; Koutsky, LA; Lupinacci, LM; Railkar, R; Suhr, G; Barr, E; Dicello, A; Li, W; Smith, JF; Tadesse, A; Jansen, KU. Early Assessment of the efficacy of a human papillomavirus types 16 L1 virus-like particle vaccine. Vaccine？2004, 22, 2936–2942.
[31]
Burchell, AN; Richardson, H; Mahmud, SM; Trottier, H; Tellier, PT; Hanley, J; Coutlée, F; Franco, EL. Modeling the sexual transmissiblitiy of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Amer. J. Epidemiol？2006, 163, 534–543.
[32]
Sanders, GD; Taira, AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis？2006, 9, 37–48.
[33]
Goldie, SJ; Grima, D; Kohli, M; Wright, TC; Weinstein, M; Franco, EL. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer？2003, 106, 896–904.
Bauch, C. A versatile ODE approximation to a network model for the spread of sexually transmitted diseases. J. Math. Biol？2002, 45, 375–395.
[36]
Dietz, K; Hadeler, K. Epidemiological models for sexually transmitted diseases. J. Mathematical Biol？1988, 26, 1–25.
[37]
Kretzschmar, M; Morris, M. Concurrent partnership and the spread of HIV. AIDS？1997, 11, 641–648.
[38]
Bauch, C; Rand, D. A moment closure model for sexually transmitted disease transmission through a concurrent partnership network. Proc. R. Soc. Lond. B？2000, 267, 2019–2027.
[39]
Kretzschmar, M; Dietz, K. The effect of pair formation and variable infectivity on the spread of an infection without recovery. Math. Biosci？1998, 148, 83–113.
[40]
Garnett, G; Kim, J; French, K; Goldie, S. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine？2006, 24, S178–S186.
[41]
Centres for disease control and prevention. Sexually Transmitted Diseases Treatment Guideline 2002. Department of Health and Human Services, 2008. 2008. Available online: http://www.cdc.gov./STD/treatment/6-2002TG.htm\#genitalWarts (accessed on January 22, 2008).
[42]
Woodman, CBJ; Collins, S; Winter, H; Bailey, A; Ellis, J; Prior, P; Yates, M; Rollason, TP; Young, LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. The Lancet？2001, 357, 1831–1836.
